【正文】 ray absorptiometryclinical evaluation of a new conebeam system. Calcif Tissue Int, 2005, 76:113–120[14]de Jong PA, Muller NL, Pare PD, et al. Computed tomographic imaging of the airways: relationship to structure and function. Eur Respir J, 2005, 26:140–152[15]Madani A, Zanen J, de Maertelaer V, et al. Pulmonary emphysema: objective quantification at multidetector row CT。 parison with macroscopic and microscopic morphometry. Radiology, 2006, 238:1036–1043[16]GarciaRio F, Miravitlles M, Soriano JB, et al. and EPISCAN Steering Committee: Systemic inflammation in chronic obstructive pulmonary disease: a populationbased study. Respiratory Research, 2010, 11: 63. doi: 10. 1186/1465–9921–11–63[17]Barnes PJ, Celli BR. Systemic manifestation and orbidities of COPD. Eur Respir J, 2009, 33: 1165–1185[18]Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med , 2006, 173: 71–78[19]Robert R. McLean. Proin?ammatory Cytokines and Osteoporosis. Current Osteoporosis Reports, 2009, 7:134–139[20]Gregory R, Mundy MD. Osteoporosis and Inflammation. Nutrition Reviews , 2007, 65: S147–S151[21]McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep , 2009 ,7:134–139.[22]Kwan TS, Padrines M, Th233。oleyre S,et al. IL6, RANKL, TNFalpha/IL1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev, 2004,15:49–60[23]Th233。oleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev, 2004, 15:457–475[24]Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic Emphysema Predicts Low Bone Mineral Density in a Tobaccoexposed Cohort. Am J Respir Crit Care Med, 2011, 183: 885–890[25]American Thoracic Society: Surveillance for respiratory hazards in the occupational setting. Am Rev Respir Dis, 1982, 126:952–956[26]ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six minute walk test. Am J Respir Crit Care Med, 2002, 116:111–117[27]Celli BR, Cote CG, Marin JM, et al. The bodymass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004, 350:1005–1012[28]Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J, 2009, 34:648–654[29]Lee TA, Weiss KB: Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004, 169:855–859[30]Li H, Manwani B, Leng SX. Fraity, inflammation and immumity. Aging Dis, 2011, 2(6):466–473. [31]Jones PW, Harding G, Berrt P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J, 2009, 34:648–654[32]Cote CG, Celli rehabilitation and the BODE index in COPDEur Respir J, 2005 , 26:630–636.[33]Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fatfree mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004, 170:1286–1293[34]Duckers JM, Evans BA, Fraser WD, et al. Low bone mineral density in men with chronic obstructive pulmonary disease. Respiratory Research, 2011, 12: 101. doi:–9921–12–101[35]Ohara T, Hirai T, Muro S, et al. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest, 2008, 134:1244–1249.[36]Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med, 2005, 26:142–153[37]Bon JM, Leader JK, Weissfeld JL, et al. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS ONE 4(8): e6865. doi:[38]Ragab AA, Nalepka JL, Bi Y, et al. Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol, 2002, 283:C679–687[39]SimonetWS, Lacey D, Dunstan C, et al. Osteoprogerin:a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309–319[40]Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenes is inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun, 1998, 247 : 610–615[41]Horowitz MC, Xi Y, Wilson K, et al. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev, 2001, 12: 9–18[42]FouqueAubert A, Chapurlat R. Influence of RANKL inhibition on immune system in the treatment of bone diseases. Joint Bone Spine, 2008, 75: 5–10[43]Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89:309–319[44]Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93:165–176[45]Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology, 2001, 142:5050–5055[46]Johannes P. Role of Cytokines in Postmenopausal Bone Loss. Current Osteoporosis Reports, 2003, 1:53–58[47]Bilgin O, Cengiz K, Kadir A et al. In?uence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL6, TNFa, TGFβ1and bone turnover markers In the treatment of postmenopausal osteoporosis. Eur Cytokine Netw., 2007, 18: 31–36[48]Mortaz E, Redegeld FA, Sarir H, et smoke stimulates the production of chemokines in mast cells. Leukoc Biol, 2008, 83:575–580.[49]Wong PK, Christie JJ, Wark JD. The effects of smoking on bone health. Clin Sci (Lond). 2007, 113: 233–241[50]Eagan T, Ueland T, Wagner PD, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J, 2010, 35: 540–548